207 related articles for article (PubMed ID: 18164805)
1. EGCG inhibits activation of the insulin-like growth factor (IGF)/IGF-1 receptor axis in human hepatocellular carcinoma cells.
Shimizu M; Shirakami Y; Sakai H; Tatebe H; Nakagawa T; Hara Y; Weinstein IB; Moriwaki H
Cancer Lett; 2008 Apr; 262(1):10-8. PubMed ID: 18164805
[TBL] [Abstract][Full Text] [Related]
2. EGCG inhibits activation of the insulin-like growth factor-1 receptor in human colon cancer cells.
Shimizu M; Deguchi A; Hara Y; Moriwaki H; Weinstein IB
Biochem Biophys Res Commun; 2005 Sep; 334(3):947-53. PubMed ID: 16053920
[TBL] [Abstract][Full Text] [Related]
3. (-)-Epigallocatechin gallate suppresses the growth of human hepatocellular carcinoma cells by inhibiting activation of the vascular endothelial growth factor-vascular endothelial growth factor receptor axis.
Shirakami Y; Shimizu M; Adachi S; Sakai H; Nakagawa T; Yasuda Y; Tsurumi H; Hara Y; Moriwaki H
Cancer Sci; 2009 Oct; 100(10):1957-62. PubMed ID: 19558547
[TBL] [Abstract][Full Text] [Related]
4. (-)-Epigallocatechin gallate inhibits growth and activation of the VEGF/VEGFR axis in human colorectal cancer cells.
Shimizu M; Shirakami Y; Sakai H; Yasuda Y; Kubota M; Adachi S; Tsurumi H; Hara Y; Moriwaki H
Chem Biol Interact; 2010 May; 185(3):247-52. PubMed ID: 20346928
[TBL] [Abstract][Full Text] [Related]
5. Preventive effects of (-)-epigallocatechin gallate on diethylnitrosamine-induced liver tumorigenesis in obese and diabetic C57BL/KsJ-db/db Mice.
Shimizu M; Sakai H; Shirakami Y; Yasuda Y; Kubota M; Terakura D; Baba A; Ohno T; Hara Y; Tanaka T; Moriwaki H
Cancer Prev Res (Phila); 2011 Mar; 4(3):396-403. PubMed ID: 21372039
[TBL] [Abstract][Full Text] [Related]
6. Insulin-like growth factor-1 receptor inhibition induces a resistance mechanism via the epidermal growth factor receptor/HER3/AKT signaling pathway: rational basis for cotargeting insulin-like growth factor-1 receptor and epidermal growth factor receptor in hepatocellular carcinoma.
Desbois-Mouthon C; Baron A; Blivet-Van Eggelpoël MJ; Fartoux L; Venot C; Bladt F; Housset C; Rosmorduc O
Clin Cancer Res; 2009 Sep; 15(17):5445-56. PubMed ID: 19706799
[TBL] [Abstract][Full Text] [Related]
7. High expression of insulin-like growth factor binding protein-3 is correlated with lower portal invasion and better prognosis in human hepatocellular carcinoma.
Aishima S; Basaki Y; Oda Y; Kuroda Y; Nishihara Y; Taguchi K; Taketomi A; Maehara Y; Hosoi F; Maruyama Y; Fotovati A; Oie S; Ono M; Ueno T; Sata M; Yano H; Kojiro M; Kuwano M; Tsuneyoshi M
Cancer Sci; 2006 Nov; 97(11):1182-90. PubMed ID: 16965600
[TBL] [Abstract][Full Text] [Related]
8. EGCG inhibits activation of HER3 and expression of cyclooxygenase-2 in human colon cancer cells.
Shimizu M; Deguchi A; Joe AK; Mckoy JF; Moriwaki H; Weinstein IB
J Exp Ther Oncol; 2005; 5(1):69-78. PubMed ID: 16416603
[TBL] [Abstract][Full Text] [Related]
9. A possible role for insulin-like growth factor-binding protein-3 autocrine/paracrine loops in controlling hepatocellular carcinoma cell proliferation.
Huynh H; Chow PK; Ooi LL; Soo KC
Cell Growth Differ; 2002 Mar; 13(3):115-22. PubMed ID: 11959812
[TBL] [Abstract][Full Text] [Related]
10. (-)-Epigallocatechin gallate prevents carbon tetrachloride-induced rat hepatic fibrosis by inhibiting the expression of the PDGFRbeta and IGF-1R.
Yasuda Y; Shimizu M; Sakai H; Iwasa J; Kubota M; Adachi S; Osawa Y; Tsurumi H; Hara Y; Moriwaki H
Chem Biol Interact; 2009 Dec; 182(2-3):159-64. PubMed ID: 19646978
[TBL] [Abstract][Full Text] [Related]
11. Role of constitutively activated and insulin-like growth factor-stimulated ERK1/2 signaling in human hepatoma cell proliferation and apoptosis: evidence for heterogeneity of tumor cell lines.
Alexia C; Lasfer M; Groyer A
Ann N Y Acad Sci; 2004 Dec; 1030():219-29. PubMed ID: 15659801
[TBL] [Abstract][Full Text] [Related]
12. Aflatoxin B1 modulates the insulin-like growth factor-2 dependent signaling axis.
Ubagai T; Kikuchi T; Fukusato T; Ono Y
Toxicol In Vitro; 2010 Apr; 24(3):783-9. PubMed ID: 20036727
[TBL] [Abstract][Full Text] [Related]
13. Epigallocatechin gallate (EGCG) attenuates high glucose-induced insulin signaling blockade in human hepG2 hepatoma cells.
Lin CL; Lin JK
Mol Nutr Food Res; 2008 Aug; 52(8):930-9. PubMed ID: 18496818
[TBL] [Abstract][Full Text] [Related]
14. Luteolin inhibits insulin-like growth factor 1 receptor signaling in prostate cancer cells.
Fang J; Zhou Q; Shi XL; Jiang BH
Carcinogenesis; 2007 Mar; 28(3):713-23. PubMed ID: 17065200
[TBL] [Abstract][Full Text] [Related]
15. (-)-Epigallocatechin gallate suppresses azoxymethane-induced colonic premalignant lesions in male C57BL/KsJ-db/db mice.
Shimizu M; Shirakami Y; Sakai H; Adachi S; Hata K; Hirose Y; Tsurumi H; Tanaka T; Moriwaki H
Cancer Prev Res (Phila); 2008 Sep; 1(4):298-304. PubMed ID: 19138973
[TBL] [Abstract][Full Text] [Related]
16. The insulin-like growth factor-I receptor inhibitor picropodophyllin-induced selective apoptosis of hepatocellular carcinoma cell through a caspase-dependent mitochondrial pathway.
E C; Li J; Shao D; Zhang D; Pan Y; Chen L; Zhang X
Oncol Res; 2013; 21(2):103-10. PubMed ID: 24406046
[TBL] [Abstract][Full Text] [Related]
17. Insulin-like growth factor type-I receptor-dependent phosphorylation of extracellular signal-regulated kinase 1/2 but not Akt (protein kinase B) can be induced by picropodophyllin.
Vasilcanu R; Vasilcanu D; Sehat B; Yin S; Girnita A; Axelson M; Girnita L
Mol Pharmacol; 2008 Mar; 73(3):930-9. PubMed ID: 18070930
[TBL] [Abstract][Full Text] [Related]
18. Selective inhibition of SCLC growth by the A12 anti-IGF-1R monoclonal antibody correlates with inhibition of Akt.
Yeh J; Litz J; Hauck P; Ludwig DL; Krystal GW
Lung Cancer; 2008 May; 60(2):166-74. PubMed ID: 18006183
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of hepatocellular carcinoma cell growth by an anti-insulin-like growth factor-I receptor monoclonal antibody.
Yue L; Wang Y; Wang H; Gao H; Liang J; Sui A; Xiang J; Zhou F; Xu C; Zhao W; Liang W; Yao R
Oncol Rep; 2012 Oct; 28(4):1453-60. PubMed ID: 22895605
[TBL] [Abstract][Full Text] [Related]
20. Insulin-like growth factor I is a comitogen for hepatocyte growth factor in a rat model of hepatocellular carcinoma.
Price JA; Kovach SJ; Johnson T; Koniaris LG; Cahill PA; Sitzmann JV; McKillop IH
Hepatology; 2002 Nov; 36(5):1089-97. PubMed ID: 12395318
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
